Deals in Depth: August 2011
Executive Summary
Merck is tasking Zymeworks' Azymetric platform for bi-specific cancer and autoimmune antibodies in a $187 million alliance. Par paid $410 million for generics company Anchen, while Baxter acquired additional medical delivery systems through its $380 million purchase of Baxa. With $334 million raised, device financing surpassed biopharma's $224 million in fundraising in August, thanks to large late-stage rounds from NeuroPace, Restoration Robotics and Entellus.You may also be interested in...
December ANDA Rush Is Largest In Two Years
December's ANDA rush has provided the largest monthly haul in two years. However, the month may be losing its influence over the US FDA's annual submission total.
Korean Pharma Highlights R&D Progress, 2020 Strategy At JPM
Among the Korean firms presenting at J.P. Morgan, Hanmi laid out its strategy for obesity and other core pipeline assets, Celltrion focused on its expanding biosimilar pipeline and China plans and LG Chem unveiled new R&D progress.
Buckle Up, Industry: EWG Finds ‘4 Million Asbestos Fiber Structures’ In Makeup For Young Girls
US House Energy and Commerce Chair Frank Pallone took note on 16 January of the Environmental Working Group’s finding of asbestos contamination in a “Princess” makeup set intended for young girls. Rep. Debbie Dingell, D-MI, will speak to the test results first, pushing her own legislation that would require asbestos testing of talc-containing children’s cosmetics in accordance with preferred methods.
Existing Subscriber?
Sign in to continue reading.
Need a specific report? 1000+ reports available
Buy Reports
Need a specific report? 1000+ reports available
Buy Reports